1  use of DAF-12 ligands to treat disseminated strongyloidiasis.

2 tate hyperinfection and, hence, disseminated strongyloidiasis.

3 l in diagnostic and epidemiologic studies of strongyloidiasis.

4 nnovative serodiagnosis method for the human strongyloidiasis.

5 ved drug efficacies against trichuriasis and strongyloidiasis.

6 f malabsorption from severe gastrointestinal strongyloidiasis.

7 7%), malaria (7%), schistosomiasis (6%), and strongyloidiasis (5%); 5% were reported healthy.

8 uding CSU might be a quite common symptom of strongyloidiasis and blastocystosis.

9 sian analyses using prevalence estimation of strongyloidiasis and onchocerciasis as two relevant exam

10 ther patient also had complete resolution of strongyloidiasis, but required a course of parenteral iv

11                         Because diagnosis of strongyloidiasis by stool examination is unreliable and

12                                          The strongyloidiasis example addresses the problem of parasi

13 and HIV/AIDS were reported from all regions, strongyloidiasis from most regions, and chronic hepatiti

14  explain the notable absence of disseminated strongyloidiasis in advanced HIV disease.

15 isease and impaired response to treatment of strongyloidiasis in some HTLV-1-infected persons.

16 es - ascariasis, trichuriasis, hookworm, and strongyloidiasis - in addition to the intestinal and liv

17 ction in serum samples from individuals with strongyloidiasis using a sandwich enzyme-linked immunoso

18 s expressing Th1, Th2, and Th17 cytokines in strongyloidiasis, we compared the frequency (Fo) of thes